Wall Street brokerages expect DURECT Co. (NASDAQ:DRRX) to post ($0.03) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for DURECT’s earnings, with estimates ranging from ($0.05) to ($0.02). DURECT reported earnings per share of $0.04 in the same quarter last year, which suggests a negative year over year growth rate of 175%. The business is expected to report its next earnings report after the market closes on Wednesday, November 7th.
On average, analysts expect that DURECT will report full year earnings of ($0.19) per share for the current fiscal year, with EPS estimates ranging from ($0.20) to ($0.17). For the next year, analysts expect that the firm will post earnings of ($0.18) per share, with EPS estimates ranging from ($0.22) to ($0.12). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow DURECT.
Separately, HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target on shares of DURECT in a research report on Tuesday, July 31st.
Shares of NASDAQ:DRRX traded up $0.05 during trading on Wednesday, reaching $1.02. The stock had a trading volume of 391,370 shares, compared to its average volume of 680,882. The company has a debt-to-equity ratio of 0.44, a current ratio of 3.60 and a quick ratio of 3.36. The firm has a market cap of $162.00 million, a PE ratio of -34.00 and a beta of 0.91. DURECT has a fifty-two week low of $0.87 and a fifty-two week high of $2.55.
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and drug delivery programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for use as raw materials in their products for pharmaceutical and medical devices under the LACTEL brand.
Further Reading: When is a capital gain realized?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.